Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients.


Coleman C., Pandya S., Wang L., BAŞER O., Cai J., Ingham M., ...Daha Fazla

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, cilt.8, ss.889-905, 2019 (SCI-Expanded, Scopus)